The timelines for cell line development and early-stage process development are decreasing, but simultaneously there has been an increase in the amount of associated data. New methods in molecular and cell biology, new analytical methods, including the application of Process Analytical Techniques (PATs) and other methods to assess product quality early on, as well as new trends in process miniaturization and automation, increase the throughput in cell line and early-stage process development and the amount of data needed to be analyzed and reviewed. Thus, data structuring and curation represents a serious bottleneck to proper data analysis and valid decision making. We have designed a highly integrated data management and workflow system, w...
Scale-down models are commonly used to execute process characterization studies, as well as to scree...
The generation of genetically engineered production CHO cell lines is normally the longest step in t...
Due to the high capital costs for a new roller bottle facility, a new suspension bioreactor perfusio...
The provision of stably expressing, high-yield mammalian cell lines is a key step in bioprocess deve...
In this talk we will present how we accelerated a clone selection process by 4 weeks while increasin...
Continuous Manufacturing (CM) is a process where perfusion cell culture for \u3e30 days is performed...
Enhancing throughput of bioprocess development has become increasingly important to rapidly screen a...
Selecting a single cell from a heterogeneous transfection pool that will scale-up appropriately from...
The scale up/down of biopharmaceutical processes is still a very challenging task. Different cell li...
Biopharmaceutical therapeutic development timelines can be reduced by quickly generating material to...
Perfusion technology has been successfully used for the commercial production of biotherapeutics, in...
The development of a successful biologic therapeutic manufacturing process begins with the creation ...
Cell line development for manufacturing is a lengthy, multi-step, resource intensive, critical path ...
The challenge during mammalian cell line and upstream process development is to identify and isolate...
The use of N-1 perfusion, coupled with high-inoculum fed batch in CHO cell culture manufacturing pro...
Scale-down models are commonly used to execute process characterization studies, as well as to scree...
The generation of genetically engineered production CHO cell lines is normally the longest step in t...
Due to the high capital costs for a new roller bottle facility, a new suspension bioreactor perfusio...
The provision of stably expressing, high-yield mammalian cell lines is a key step in bioprocess deve...
In this talk we will present how we accelerated a clone selection process by 4 weeks while increasin...
Continuous Manufacturing (CM) is a process where perfusion cell culture for \u3e30 days is performed...
Enhancing throughput of bioprocess development has become increasingly important to rapidly screen a...
Selecting a single cell from a heterogeneous transfection pool that will scale-up appropriately from...
The scale up/down of biopharmaceutical processes is still a very challenging task. Different cell li...
Biopharmaceutical therapeutic development timelines can be reduced by quickly generating material to...
Perfusion technology has been successfully used for the commercial production of biotherapeutics, in...
The development of a successful biologic therapeutic manufacturing process begins with the creation ...
Cell line development for manufacturing is a lengthy, multi-step, resource intensive, critical path ...
The challenge during mammalian cell line and upstream process development is to identify and isolate...
The use of N-1 perfusion, coupled with high-inoculum fed batch in CHO cell culture manufacturing pro...
Scale-down models are commonly used to execute process characterization studies, as well as to scree...
The generation of genetically engineered production CHO cell lines is normally the longest step in t...
Due to the high capital costs for a new roller bottle facility, a new suspension bioreactor perfusio...